Q2 2024 EPS Estimates for GlycoMimetics, Inc. (NASDAQ:GLYC) Cut by Analyst

GlycoMimetics, Inc. (NASDAQ:GLYCFree Report) – HC Wainwright decreased their Q2 2024 earnings per share estimates for GlycoMimetics in a report released on Tuesday, June 4th. HC Wainwright analyst E. White now forecasts that the biotechnology company will post earnings per share of ($0.15) for the quarter, down from their previous estimate of ($0.13). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for GlycoMimetics’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for GlycoMimetics’ Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.54) EPS and FY2026 earnings at ($0.10) EPS.

GLYC has been the subject of a number of other reports. StockNews.com started coverage on GlycoMimetics in a research report on Friday. They set a “sell” rating for the company. Capital One Financial downgraded GlycoMimetics from an “overweight” rating to an “equal weight” rating in a research report on Monday, May 6th.

Check Out Our Latest Stock Analysis on GLYC

GlycoMimetics Trading Down 3.9 %

GlycoMimetics stock opened at $0.26 on Thursday. The company has a market capitalization of $16.78 million, a PE ratio of -0.45 and a beta of 2.15. GlycoMimetics has a 12 month low of $0.26 and a 12 month high of $3.53. The stock has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $2.16.

GlycoMimetics (NASDAQ:GLYCGet Free Report) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01).

Institutional Investors Weigh In On GlycoMimetics

A number of hedge funds have recently added to or reduced their stakes in the business. Acuta Capital Partners LLC acquired a new stake in GlycoMimetics in the third quarter valued at approximately $41,000. Advisor OS LLC acquired a new stake in GlycoMimetics in the fourth quarter valued at approximately $238,000. MJP Associates Inc. ADV acquired a new stake in GlycoMimetics in the fourth quarter valued at approximately $238,000. Finally, Vanguard Group Inc. grew its stake in GlycoMimetics by 14.0% in the first quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock valued at $8,286,000 after acquiring an additional 340,112 shares during the period. 75.19% of the stock is currently owned by institutional investors.

About GlycoMimetics

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.

See Also

Earnings History and Estimates for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.